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Scleroderma is a disorder characterized by ®brosis of
the skin and internal organs and autoimmunity.
Whereas the cause is unknown, interleukin-4 and
transforming growth factor-b have been postulated
to play a major part in the ®brosis. To investigate
the part played by these cytokines, we prepared
TSK/+ mice with a targeted mutation in the inter-
leukin-4Ra or transforming growth factor-b genes.
The breeding failed to produce TSK/+ transforming
growth factor-b ±/± mice so analysis of the role of
transforming growth factor-b was limited to TSK/+
transforming growth factor-b +/± mice. We observed
that TSK/+ interleukin-4Ra ±/± did not develop der-
mal thickening, and deletion of one allele of the
transforming growth factor-b gene resulted in
diminished dermal thickness compared with TSK/+
mice; however, the deletion of interleukin-4Ra or
transforming growth factor-b had no effect on lung
emphysema, which is another characteristic of TSK
syndrome. Electron microscopic analysis of skin
showed that the collagen ®brils in TSK/+ interleu-
kin-4Ra ±/± mice exhibit normal periodicity but
have a smaller diameter than the ®bers found in
C57BL/6 mice. Analysis of skin and serum samples
showed that the deletion of interleukin-4Ra or one
allele of transforming growth factor-b prevented the
increase of skin thickness paralleled with a decrease
in the dermal hydroxyproline content and develop-
ment of autoantibodies associated with TSK syn-
drome. These results demonstrate the importance of
interleukin-4 and transforming growth factor-b for
the development of cutaneous ®brosis in vivo and
suggest an important part for these cytokines in
wound healing and connective tissue maintenance in
general. Key words: emphysema, interleukin-4R, trans-
forming growth factor-b sclerosis, tight skin. J Invest
Dermatol 116:136±143, 2001
T
he TSK mouse bears a chromosome 2 mutation that
results in increased synthesis and accumulation of
collagen in the skin and internal organs and causes
lung emphysema (Green et al, 1976). It has been
proposed that a partially duplicated ®brillin 1 (pdFbn-
1) gene is the mutation responsible for the scleroderma-like
syndrome of TSK/+ mice (Siracusa et al, 1996). This hypothesis is
strongly supported by ®ndings demonstrating that the TSK
phenotype and pdFbn-1 cosegregate (Kasturi et al, 1997); however,
the mechanisms through which this mutation in¯uences the
increased synthesis and deposition of collagen that represents the
endpoint of cutaneous hyperplasia is not known.
The immune system, and particularly T cells, may play a part in
this process as TSK/+ JHD ±/± mice develop cutaneous hyperplasia
and C57BL/6 pa/pa mice infused with major histocompatibility
complex haplotype matched TSK/+ bone marrow cells develop a
scleroderma-like syndrome (Phelps et al, 1993; Wallace et al, 1994).
A possible means through which T cells may participate in the
induction of ®brosis is suggested by the ®nding that interleukin (IL)
±4 and transforming growth factor (TGF) -b, both secreted by T
cells, increase the synthesis of collagen by ®broblasts (Postlethwaite,
1995). Although TSK/TSK homozygous embryos die in utero by
day 9 of pregnancy, cutaneous hyperplasia in TSK/+ mice is
evident 2 wk after birth. To investigate the effect of these cytokines
on the development of the TSK syndrome, we prepared TSK/
+ IL-4Ra ±/± and TSK/+ TGF-b +/± mice. Here we show that
targeted mutations in the IL-4Ra and in one TGF-b allele prevent
the occurrence of cutaneous hyperplasia, and lowers the levels of
dermal hydroxyproline and serum concentrations of autoantibo-
dies. Interestingly, these targeted mutations do not affect the
development of lung emphysema suggesting that other genes
contribute to this pathologic syndrome.
MATERIALS AND METHODS
Mice C57BL/6 pa/pa, and TSK/+ mice were purchased from the
Jackson Laboratory (Bar Harbor, ME). We used TSK/+ mice obtained by
the breeding of TSK/+ 3 C57BL/6 pa/pa mice (H-2b) as previously
described (Green et al, 1976). BALB/C IL-4Ra ±/± mice (H-2d) mice
bearing targeted mutations in IL-4Ra (Noben-Trauth et al, 1997) and
C57BL/6 (H-2b) mice bearing a targeted mutation in TGF-b (Kulkarni
et al, 1992) genes were produced at NIH Animal Facilities whereas Mov/+
mice were produced by R. Jaenisch (MIT, Boston MA) (Schnieke et al,
1983). TSK/+ IL-4Ra ±/± mice were obtained by mating TSK/+ IL-
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4Ra +/± mice and TSK/+ TGF-b +/± mice were obtained by breeding
TSK/+ and TGF-b +/± mice. Fibroblast lines were obtained from 9 d old
C57BL/6 pa/pa, TSK/+, and Mov/Mov embryos as previously described
(Kasturi et al, 1997).
Reagents The Fbn-1 fusion protein was prepared as previously described
(Murai et al, 1998). Other reagents were purchased from Sigma (St Louis,
MO) unless otherwise noted.
Identi®cation of TSK mutant and of TGF-b and IL-4R null
alleles Genomic DNA were prepared from tail biopsies with Quiagen
Tissue Kits (Quiagen, Hilden, Germany). Polymerase chain reaction
analysis was preformed for identi®cation of pdFbn-1 gene with a forward
primer of 5¢-GTTGGCAACTATACCTGCAT-3¢ and a reverse primer of
5¢-CCTTTCCTGGTAACATAGGA-3¢. Cycling conditions were 95°C
for 1 min primary denaturation, then 95°C, 59°C for 1 min, 72°C for 45 s
for 30 cycles in a 50 ml volume. Polymerase chain reaction for the wild-type
TGF-b allele was carried out with the forward primer 5¢-TCACCCGCG-
TGCTAATGGTGGACCGC-3¢ and reverse primer of 5¢-ACACCTTC-
CATTCTCTTGAGCTGGG-3¢, and for the disrupted TGF-b allele with
the forward primer of 5¢-CATGGAGCTGGTGAAACGGAAGCGC-3¢
and the reverse primer of 5¢-TCCATCTGCACGAGACTAGT-3¢ under
the cycle conditions described above.
Polymerase chain reaction for the wild-type IL-4R allele was done with
the forward primer of 5¢-AATGTGACCTACAAGGAACC-3¢ and
reverse primer of 5¢-GGACTCCACTCACTCCAG-3¢, and for the
disrupted IL-4R allele with the forward primer of 5¢-CTTGGGTGGAG-
AGGCTATTC-3¢ and the reverse primer of 5¢-AGGTGAGATGACAG-
GAGATC-3¢ under the same cycle conditions.
Southern blotting Genomic DNA were prepared from ®broblasts
obtained from 9 d old embryos produced by the breeding of Mov/+ mice.
Samples (10 mg) of genomic DNA were digested with the appropriate
restriction enzymes, separated by electrophoresis on a 1% agarose gel, and
blotted on to nitrocellulose ®lters. The ®lters were hybridized with a nick
translated 32P-labeled a1 collagen type 1 probe at 42°C in hybridization
solution containing 50% formamide and ®nally washed in 0.2 3 sodium
citrate/chloride buffer containing 0.1% sodium dodecyl sulfate at 65°C.
Light and electron microscopy Skin samples (4.0 cm2) were removed
from the dorsal side immediately below the neck in a manner that
minimized stress. The samples were ®xed for 16 h in buffered saline
containing formalin, cut into 2±3 mm wide longitudinal strips, dehydrated,
and embedded in paraf®n and stained with hematoxylin±eosin according to
routine histologic methods. The thickness of the skin was determined by
measuring it from the top of the granular layer to the junction between the
dermis and subcutaneous fat on hematoxylin±eosin-stained sections.
Skin tissues for electron microscopy were processed following standard
techniques. Each sample was assigned a random number and the diameter
of the collagen ®bers was measured blindly as previously described (Phelps
et al, 1993).
In¯ated lungs after harvesting were ®xed and processed by the same
methods described above. The extent of airspace was analyzed on
hematoxylin±eosin-stained sections.
Determination of skin hydroxyproline content Punch biopsies
(6 mm diameter) from shaved skin samples were treated with
chloroform/methanol (2:1 vol/vol) to remove fat and dried by Speedvac
centrifugation. Dried samples were weighed and acid hydrolyzed for 24 h at
110°C. The hydroxy lysates were dried, redissolved in 200 ml of water and
®ltered through millipore ®lters. Sample aliquots of 20 ml were diluted 10-
fold and used for the analysis of amino acid composition in a Hewlett-
Packard Amino Acid Analyzer. The quantity of hydroxyproline is
expressed as (mol per mg dry skin (Hatakeyama et al, 1996).
Quantitation of serum anti-topoisomerase I and anti-®brillin 1
antibodies Serum anti-topoisomerase I and anti-®brillin 1 levels were
measured by radioimmunoassay as previously described (Muryoi et al, 1992;
Murai et al, 1998). Brie¯y, microtiter plates were coated with 3 mg per ml of
puri®ed topoisomerase I (GibcoBRL, Gaithersburg, MD) or 1 mg per ml of
Fbn-1 fusion protein in carbonate buffer, pH 9.6, washed with phosphate-
buffered saline, blocked with 1% bovine serum albumin in phosphate-
buffered saline and incubated for 90 min at room temperature with a 1:30
dilution of serum samples. After extensive washing, the plates were
incubated with 50,000 cpm of 125I-labeled rat anti-mouse k per well for
90 min. Bound radioactivity was measured in a g spectrometer.
Cell culture and measurement of collagen synthesis C57BL/6 pa/
pa and TSK/+ primary ®broblast lines were maintained in DMEM
supplemented with 100 U per ml penicillin 100 mg per ml streptomycin and
10% fetal bovine serum (Mediatech, Herndon, VA). Collagen production
was measured using a modi®ed version of the protocol described by
Peterkofsky and Diegelmann (1970). Brie¯y, ®broblasts were grown to
con¯uence in 75 cm2 ¯asks, detached via trypsinization and plated at a
density of 105 cells per well in 24 well plates. The cells were washed with
phosphate-buffered saline and the media was replaced with proline free
DMEM supplemented with 3 mCi per well 3H-proline (Amersham,
Piscataway, NJ), 50 mg per ml ascorbic acid, and b-aminopropionitrile
and with 400 U per ml recombinant murine IL-4 (Pharmingen, San Diego,
CA), 10 ng per ml recombinant human TGF-b1 or 0.5±50 ng per ml IL-13
(R&D Systems, Minneapolis, MN). After a 24 h incubation, the media
were collected for determination of collagen synthesis and the cell numbers
were counted. To measure collagen synthesis, 100 ml aliquots of media
from labeled ®broblast were incubated at 37°C for 18 h in either the
presence or absence of highly puri®ed bacterial collagenase (Sigma) at a
concentration of 200 U per aliquot. The samples were then extensively
dialyzed in microdialysis chambers (Pierce, Rockford, IL) against
phosphate-buffered saline at 4°C to remove unincorporated 3H-proline
and digested collagen. The total counts per sample were then determined
utilizing a liquid scintillation counter. Biosynthetic labeling of collagen was
estimated by subtracting the cpm of the collagenase-digested dialysis
retentate from the cpm of the dialysis retentate which had no collagenase
added.
Statistical analysis Statistical signi®cance between groups was measured
using the unpaired Student's t test. p < 0.05 was considered to be
signi®cant.
RESULTS
Increase of collagen synthesis by ®broblast incubated with
IL-4 and TGF-b IL-4 and TGF-b have been reported to
upregulate the expression of collagen genes (Postlethwaite, 1995).
We studied the synthesis of collagen by ®broblast lines from
C57BL/6 pa/pa and TSK/+ mice cultured for 20 h in media alone
or in the presence of 400 U per ml of IL-4 or 10 ng per ml of TGF-
b (Fig 1A). Collagen synthesis by normal ®broblasts was increased
2-fold upon the addition of IL-4 or TGF-b. In addition, there was
a highly signi®cant increase of collagen synthesis by TSK/+
®broblast after incubation with either cytokine; however, no
signi®cant increase of collagen synthesis was observed after
incubation of ®broblasts with 0.5±50 ng per ml of IL-13 (data not
shown). This result is somewhat unexpected as IL-4 and IL-13
utilize the IL-4Ra chain and have generally been shown to possess
similar functions in vivo.
The speci®city of the assay was determined by studying the
synthesis of collagen by Mov/Mov ®broblasts. The genotypes of
Figure 1. Synthesis of collagen by normal and TSK/+ ®broblasts
upon incubation with IL-4 and TGF-b. Bars represent the mean value
for quadruplicate samples of 105 ®broblast +/± the SD. The experiment
was repeated three times with similar results.
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these ®broblasts were determined by southern blotting (data not
shown). As can be seen in Fig 1, Mov/Mov ®broblasts failed to
synthesize collagen consistent with the ®nding that a retroviral
insertion has occurred in the a1 collagen type I gene inactivating it
(Schnieke et al, 1983). These results show that both IL-4 and TGF-
b upregulate the expression of collagen genes by ®broblasts from
both TSK/+ and normal mice. In addition, these results
demonstrate that TSK/+ ®broblasts secrete signi®cantly higher
levels of collagen when compared with C57BL/6 ®broblasts in the
basal state.
Crossing of TSK/+ mice with mice bearing targeted
mutations in the IL-4R and TGF-b genes Heterozygous
viable TSK/+ pa/pa mice were obtained by crossing TSK/+ pa/pa
mice with C57BL/6 pa/pa mice. The TSK mutation was originally
described in a B10D2 (H-2d) mouse, which was maintained in
C3HDi (H-2b) background and subsequently transferred to the
C57BL/6 pa/pa (H-2b) background (Green et al, 1976).
Occurrence of cutaneous hyperplasia in these different genetic
backgrounds, as well as in TSK/+ vit/vit (Hatakeyama et al, 1996)
or TSK/+ NZB/+ mice (Bocchieri et al, 1993) demonstrates that
the occurrence of TSK syndrome is independent of genetic
background.
TSK/+ mice bearing a targeted mutation in the TGF-b gene
were obtained by crossing TSK/+ pa/pa mice with TGF-b +/±
mice on the C57BL/6 (H-2b) background, and TSK/+ IL-4R ±/±
Figure 2. Histopathology of the skin from TSK/+ IL-4R+/±, TSK/+ IL-4R±/±, or TSK/+ TGF-b +/± mice. Paraf®n-embedded sections were
stained with hematoxylin±eosin. Scale bar: 100 mM.
Figure 3. Histopathology of the lung from TSK/+ IL-4R+/±, TSK/+ IL-4R ±/±, and TSK/+ TGF-b +/± mice. Paraf®n-embedded sections
were stained with hematoxylin±eosin. Scale bar: 1.6 mM. Lung sections from two TSK/+ TGF-b +/± mice are presented. As can be seen in one mouse,
strong cellular in®ltration has occurred in the interstitium (bottom right).
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mice were obtained from sister±brother crossing of TSK/+ IL-
4Ra +/± (H-2db) mice. The progeny from both crossings were
genotyped by polymerase chain reaction as described in Materials
and Methods.
From the breeding of TSK/+ IL-4R +/± mice we studied 71
mice: 36 expressing the TSK mutation (TSK/+) and 35 lacking the
mutation (+/+). Among the 36 TSK/+ mice, nine were IL-
4Ra ±/±, 23 were IL-4Ra +/±, and four were IL-4Ra +/+.
From the breeding of TSK/+ TGF-b +/± mice we studied 85
progeny: 43 expressed the TSK mutation (TSK/+) and 42 did not
(+/+). Among the 43 mice bearing the TSK mutation, 37 were
TGF-b +/±, six were TGF-b +/+, and none exhibited the TGF-
b ±/± genotype. It is noteworthy that among 42 mice lacking the
TSK mutation (±/±) we obtained only three TGF-b ±/± mice,
which is in agreement with previous ®ndings that indicate a high
mortality rate (> 50%) in utero for mice lacking a functional TGF-b
gene (Christ et al, 1994). The absence of the TSK/+ TGF-b ±/±
genotype in our crossings may suggest that unknown epistatic gene
interactions prevent the development of mice possessing this
genotype.
Histopathology of skin and lung of TSK/+ mice expressing
a targeted mutation in the IL-4R or TGF-b
gene Histopathology of the skin and lung was studied in 3 mo
old mice. Figure 2 shows skin alterations in TSK/+ mice and the
normal structure of skin of C57BL/6 pa/pa mice. TSK/+ mice
exhibit cutaneous hyperplasia characterized by increased deposition
of collagenous material in the super®cial and deep dermis extending
around adnexa and the paniculum carnosum associated with the
disappearance of fat tissue and a reduced number of hair follicles. In
contrast, TSK/+ IL-4Ra ±/± mice show lack of dermal thickening,
whereas TSK/+ IL-4Ra +/± mice showed a moderate thickening
of the skin in which the fatty tissue is preserved (Fig 3). In the same
®gure the skin sections of the two TSK/+ TGF-b +/± mice
presented show that skin thickness is slightly decreased compared
with TSK/+ mice with preservation of fat tissue and hair follicles;
however, it should be pointed out that in one mouse cellular
in®ltration in the deep dermis was observed (Fig 2, center bottom
picture). Only one TSK/+ TGF-b +/+ mouse was analyzed for
TSK syndrome and showed a skin thickness of 200 mm, a
hydroxyproline concentration of 1054 mmol per mg,
autoantibody levels of 4448 and 9851 cpm for anti-topoisomerase
I and anti-®brillin 1, respectively, and the presence of pulmonary
emphysema.
The lungs of C57BL/6 mice appeared normal, with small alveoli
of approximately the same size. By contrast, TSK/+ lungs displayed
enlarged alveoli that were three to four times larger than normal
mice (Fig 3) in agreement with the description of Rossi et al
(1984). TSK/+ IL-4Ra ±/± and TSK/+ TGF-b +/± mice, like
TSK/+ and TSK/+ IL-4Ra +/± mice showed a histologic picture
of emphysema (Fig 3).
Electron microscopy analysis Electron microscopic
examination of the skin con®rmed the observations by light
microscopy and allowed a more detailed analysis. In contrast to
C57BL/6 pa/pa mice (Fig 4A), where there was no excessive
deposition of collagen in the deep dermis and regular collagen
bundles were found, the skin from TSK/+ mice (Fig 4B) showed
abundant irregular and wavy collagen bundles. TSK/+ IL-4Ra ±/±
and TSK/+ TGF-b +/± skin did not exhibit any alteration of the
collagen bundles. Figure 5 shows that in C57BL/6 pa/pa mice,
large ®bers (70±130 nm) were predominant whereas in TSK/+
skin, small diameter ®bers (50±100 nm ®bers) were predominant.
In studies carried out on skin biopsies of human scleroderma
patients the predominance of small diameter ®bers was considered
pathognomonic for neo®brogenesis (Flieischmajer et al, 1991).
Predominance of small diameter ®bers was observed in TSK/+ IL-
4Ra ±/± skin (70±110 nm) and TSK/+ IL-4Ra +/± skin (70±
100 nm). TSK/+ TGF-b +/± skin also displayed small diameter
®bers (40±90 nm). Thus, electron microscopic analysis and size of
Figure 4. Electron microscopy of dermis and collagen bundles in the skin of C57BL/6 pa/pa (A), TSK/+ (B), TSK/+ IL-4R ±/± (C), TSK/+ IL-4R +/±
(D), and TSK/+ TGF-b +/± (E) mice.
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collagen ®bers revealed that the IL-4Ra ±/± and TGF-b +/±
genotype did not rescue all the skin abnormalities of TSK/+ mice.
TSK syndrome in TSK/+ mice bearing targeted mutations
in IL-4R or TGF-b genes Hatakeyama et al (1996) have shown
that there is a striking correlation between the histologic and
biochemical alterations in the skin of TSK/+ mice and the
occurrence of anti-topoisomerase I antibodies. We used
Hatakeyama's parameters to de®ne the TSK syndrome
determining the skin thickness, concentration of dermal
hydroxyproline, and the presence of anti-topoisomerase I
autoantibodies. Murai et al (1998) showed that anti-®brillin 1
autoantibodies are present in TSK/+ mice, but not in C57BL/6
pa/pa mice; thus, anti-®brillin 1 autoantibodies were also analyzed
in our study. Table I shows that in TSK/+ mice there is a
signi®cant increase in skin thickness (p = 0.02), hydroxyproline
content (p = 0.01), anti-topoisomerase I antibodies (p = 0.002), and
anti-®brillin 1 antibodies (p = 0.004) compared with C57BL/6 pa/
pa mice. In TSK/+ IL-4Ra ±/± mice, the thickness of the skin and
dermal hydroxyproline content were similar to C57BL/6 pa/pa
mice and were considerably reduced when compared with TSK/+
mice. In contrast, in TSK/+ IL-4Ra +/± mice the skin thickness
was increased compared with normal mice (p = 0.018); there was
also an increase in hydroxyproline content, although it was not
statistically signi®cant (p = 0.26); however, both skin thickness and
hydroxyproline content of TSK/+ IL-4Ra +/± skin was
signi®cantly greater than that of TSK/+ IL-4Ra ±/± skin. With
respect to autoantibodies, TSK/+ IL-4Ra +/± mice show a
signi®cant increase of anti-topoisomerase I compared with
normal mice and TSK/+ IL-4Ra ±/± mice; however, TSK/+ IL-
4Ra +/± mice did not display a signi®cant increase in anti-®brillin
1 antibodies compared with either normal mice or TSK/+ IL-
4Ra ±/± mice.
As the comparison of TSK syndrome parameters between TSK/
+ IL-4Ra ±/± mice and C57BL/6 mice is biased because of
genetically different backgrounds we compared the TSK syndrome
between TSK/+ IL-4Ra ±/± and TSK/+ IL-4Ra +/+ mice. We
found a signi®cant decrease in the skin thickness (p = 0.02), dermal
Figure 5. Histogram showing the distribution of
diameter of collagen ®bers present in the mid-der-
mis of C57BL/6 pa/pa (A), TSK/+ (B), TSK/
+ IL-4R ±/± (C), TSK/+ IL-4R +/± (D), and
TSK/+ TGF-b +/± (E) mice.
Table I. TSK syndrome in TSK/+IL-4Ra±/± and TSK/+TGF-b+/± micea
Autoantibodies speci®c for
Mouse strain N Skin thickness
(mm)
Hydroxyproline content
(mmol/mg dry skin)
Topo-I
(cpm)
Fbn-I
(cpm)
C57BL/6 pa/pa 6 132 6 42 xp xxp 518 6 88 xp xxp 512 6 472 xp xxp 1379 6 12 xp xxp
TSK/+ pa/+ 13 228 6 72 0.02 1035 6 310 0.01 2733 6 337 0.002 11196 6 49 0.004
TSK/+IL-4Ra+/± 9 243 6 88 0.018 } 0.02 804 6 167 0.26 } 0.005 1180 6 649 0.07 } 0.06 3409 6 25 0.08 } 0.8TSK/+IL-4Ra±/± 9 135 6 31 0.2 492 6 244 0.12 607 6 421 0.66 366 6 18 0.03
+/+TGF-b+/± 3 120 6 18 0.6 } 0.019 441 6 100 0.4 } 0.4 737 6 30 0.37 } 0.85 4967 6 10 0.026 } 0.14TSK/+TGF-b+/± 16 164 6 78 0.16 442 6 217 0.16 446 6 248 0.77 2850 6 14 0.06
aValues represent mean values 6 standard deviation (SD). xp, value comparing various strains to wild type C57BL/6 pa/pa mice; xxp, value comparing genotypically
similar strains.
140 MCGAHA ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
hydroxyproline content (p = 0.05), and anti-topoisomerase I
antibodies (p = 0.06), but not in the case of anti-®brillin 1
antibodies (p = 0.8) in TSK/+ IL-4Ra ±/± compared with TSK/
+ IL-4Ra +/± mice. In addition, both TSK/+ IL-4Ra ±/± and
TSK/+ IL-4Ra +/± mice develop emphysema.
TSK/+ TGF-b +/± mice displayed no signi®cant increase in skin
thickness (p = 0.144), dermal hydroxyproline content (p = 0.16),
anti-topoisomerase I antibodies (p = 0.07), or anti-®brillin 1
antibodies (p = 0.6) compared with normal mice; however, we
found signi®cant differences between the skin thickness when
comparing TSK/+ TGF-b +/± with +/+ TGF-b +/± mice
(p = 0.019).
Thus in the absence of IL-4Aa and when only one copy of a
functional TGF-b gene is present several of the important aspects of
the TSK syndrome (skin thickness, increased hydroxyproline, and
increased anti-topoisomerase I antibodies) were decreased.
DISCUSSION
In this study we examined the part that TGF-b and IL-4 play in the
development of TSK syndrome. Initially, we demonstrated that
increased synthesis of collagen by normal and TSK/+ ®broblasts
occurred upon short exposure to IL-4 and TGF-b. This outcome is
in agreement with several reports that have found both IL-4 and
TGF-b to upregulate expression of the type 1 collagen genes
(Fertin et al, 1991; Serpier et al, 1997; Cotton et al, 1998; Ichiki et al,
1997; Inagaki et al, 1994). Similarly, we demonstrated that TSK/+
®broblasts spontaneously produce more collagen than C57BL/6
pa/pa derived ®broblasts and a greater increase in collagen
production is observed in response to stimulation with either IL-
4 or TGF-b. Serpier et al (1997) made similar observations when
they found that ®broblasts from scleroderma patients produce more
collagen than their normal counterparts, express higher levels of IL-
4Ra, and produced greater levels of collagenase-digestible protein
after stimulation with IL-4. In addition, scleroderma ®broblasts
have been reported to express higher levels of TGF-bRI and TGF-
bRII and to bind higher levels of 125I-labeled TGF-b than normal
®broblasts (Kawakami et al, 1998) suggesting that scleroderma
®broblasts are more sensitive to pro®brotic stimuli from TGF-b or
IL-4.
There are no available data on the in vivo effect of these cytokines
on the ®brotic processes. To address this question, we generated
TSK/+ IL-4Ra ±/± and TSK/+ TGF-b +/± mice. It is note-
worthy that whereas TSK/+ mice exhibiting a targeted mutation in
TGF-b genes were generated in the C57BL/6 (H-2b) background,
TSK/+ IL-4Ra ±/± mice had a mixed genetic background (H-2d,
H-2b, and H-2db) as illustrated by coat color: two white, three
black, and six agouti. We believe, however, that the mixed genetic
background did not alter the development of TSK syndrome for
three reasons: (i) It was shown that the occurrence of cutaneous
hyperplasia is solely due to the TSK mutation and is not affected by
various genetic backgrounds (Green et al, 1976); (ii) it was shown
that TSK/+ JHD ±/± (Kasturi et al, 1997) and TSK/+ RAG2 ±/±
mice (Siracusa et al, 1998), which were bred in a manner similar to
that described here and have the same genetic background as the
IL-4Ra ±/± mice, developed cutaneous hyperplasia; and (iii) as
TSK/+ IL-4Ra ±/± mice were not obtained on the C57BL/6
background, the results in our study were always compared with
TSK/+ IL-4Ra +/± mice, which have a similar genetic back-
ground.
We showed that disruption of the IL-4Ra gene results in
reduced ®brotic development in TSK/+ mice. The lack of
cutaneous hyperplasia in TSK/+ IL-4Ra ±/± mice was observed
throughout their life (thickness of skin was 151 6 51 mm in 3 mo
old mice and 150 6 70 mm in 6 mo old mice) indicating that IL-
4Ra signaling is important in the development of ®brosis in TSK/
+ mice. In the case of TSK/+ TGF-b +/± mice, we also observed a
decrease in skin thickness. It was originally reported that TGF-
b +/± mice do not exhibit an altered phenotype (Shull et al, 1992;
Christ et al, 1994); however, recent studies show a defect in wound
healing in TGF-b +/± mice (Ashcroft et al, 1999) indicating a
phenotypically dominant effect in heterozygous TGF-b KO mice.
This may have particular relevance to our observations of decreased
skin thickness in TSK/+ TGF-b +/± mice as it was previously
shown that TGF-b transcripts were signi®cantly elevated in the
skin of TSK/+ mice when compared with pa/pa mice (Phelps et al,
1993). It is possible that the development of cutaneous hyperplasia
in TSK/+ requires a certain threshold level of TGF-b, which is not
achieved by the disruption of one of the TGF-b alleles. This would
be consistent with the observation that TGF-b transcripts in
heterozygous animals was approximately half of the level of TGF-b
+/+ mice (Kulkarni et al, 1993).
A morphometric study of collagen ®bers shows that in the skin of
TSK/+ mice, TSK/+ IL-4Ra +/±, and TSK/+ TGF-b +/± mice
small diameter ®bers predominate. This outcome suggests that the
lack of TGF-b or IL-4Ra does not totally correct the defects
associated with TSK syndrome and is supported by earlier studies
where small diameter ®bers of collagen in the skin were interpreted
as a sign of neo®brogenesis (Flieischmajer et al, 1991). These results
were in sharp contrast to the diameter of ®brils in C57BL/6 pa/pa
control mice in which the large diameter ®bers were dominant
(Fig 5).
Because of these results, we examined the effect of disruption of
IL-4Ra and TGF-b genes on the TSK syndrome. Compared with
TSK/+ mice, TSK/+ IL-4Ra ±/± and TSK/+ TGF-b +/± mice
did not develop autoantibodies against the scleroderma antigens
topoisomerase I (Shero et al, 1986) and ®brillin 1 (Tan et al, 1999).
In the case of TSK/+ IL-4Ra ±/± mice, this may be explained as
IL-4 signaling plays an important part in the development of TH
cells cooperating with B cells in the production of autoantibodies.
In the case of TGF-b de®cient mice, however, the lack of this
cytokine may skew the immune responses towards a Th1 type
response and away from antibody production. Li et al (1999) found
that the neutralization of TGF-b aided mice in the clearance of the
pathogen Leishmania major via enhanced cell-mediated immunity.
In addition, it has been shown that TGF-b decreases interferon-g
and tumor necrosis factor-a production by T cells (Holter et al,
1994; Erard et al, 1999), and the deletion of TGF-b induces
in¯ammatory reactions (Shull et al, 1992). Therefore, it is likely that
the animals with a targeted disruption in the TGF-b gene produce a
more in¯ammatory cytokine pro®le and, thus, have a lower
antibody titer.
It was very striking that the disruption of these two genes does
not affect the development of lung emphysema. This is interesting
because ®brillin 1 is an important component of micro®bers in the
lung (Sakai et al, 1986). In principle, the mutated ®brillin 1 in TSK/
+ mice is likely to be responsible for the alveolar wall abnormalities;
however, the presence of emphysema with a lack of skin ®brosis
indicates a disassociation of the effect of disruption of IL-4Ra and
TGF-b genes on cutaneous hyperplasia and emphysema. This result
strongly suggests that factors other than IL-4 and TGF-b are
responsible for the emphysema. This concept is supported by our
own previous results demonstrating that Tg mice expressing the
partially duplicated Fbn-1 gene also develop a scleroderma-like
syndrome and, interestingly, newborn mice injected with a plasmid
encoding the mutated Fbn-1 gene develop localized scleroderma
but lack pulmonary emphysema (Saito et al, 2000).
These results suggest that IL-4 and TGF-b in¯uence ®brosis in
vivo. Nevertheless it is unclear what the source of these cytokines
may be as TSK/+ mice begin to exhibit skin ®brosis by 2 wk of
age. There is little information on the synthesis of IL-4 and TGF-b
in embryonic life. Eosinophils, which are able to produce IL-4, can
be excluded because no eosinophilic in®ltration has been observed
in the dermis of TSK/+ mice (Green et al, 1976); therefore, other
cell types are likely to be responsible for the cutaneous hyperplasia.
For instance mastocytes, which are present in increased numbers in
the skin of TSK/+ mice (Green et al, 1976; Phelps et al, 1993;
Ridge et al, 1996), CD4+ T cells, and the ®broblast themselves have
been reported to be capable of synthesizing IL-4 and TGF-b. In the
case of ®broblasts, it has been demonstrated that scleroderma
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®broblasts spontaneously produce high levels of IL-4 in vivo and in
vitro in the absence on stimuli from other cell types (White et al,
1992; Salmon-Ehr et al, 1996). Whereas the transcript for TGF-b
was found to be increased in the skin of TSK/+ mice (Phelps et al,
1993), there is no information whether the IL-4 transcript is
increased. The evidence for an in vivo effect of IL-4 in TSK
cutaneous hyperplasia is provided by our observation that TSK
®broblasts synthesize more collagen in response to IL-4 stimulation
when compared with C57BL/6 ®broblasts and Ong et al (1998)
reported that the injection of anti-IL-4 antibodies in TSK neonates
prevented cutaneous hyperplasia.
As stated above, both IL-4 and TGF-b upregulate the expression
of collagen genes. This means that in mice with targeted mutations
in IL-4Ra, the TGF-b genes should be able to compensate for the
IL-4 defect. Likewise, in TGF-b +/± mice IL-4 should compensate
for the TGF-b defect; however, in TSK/+ IL-4Ra ±/± and, to a
lesser extent, in TSK/+ TGF-b +/± mice, we observed that a
targeted mutation prevented cutaneous hyperplasia. Two possible
hypothesis can be suggested to explain these results. First, the
production of TGF-b requires IL-4. Elovic et al (1999) have shown
that the presence of IL-4 is necessary for the production of TGF-b.
Additionally, it has been shown that IL-4 upregulates the
production of TGF-b in T cells whereas TGF-b downregulates
the production of IL-4 (Holter et al, 1994; Seder et al, 1998; Elovic
et al, 1999). Therefore, IL-4 may serve as a physiologic molecular
switch for gene expression of TGF-b. In this scenario IL-4 would
be the inducer of ®brosis by elevating TGF-b production;
however, once TGF-b was induced it would act as a positive
regulator of its own expression via an autocrine pathway
(Kawakami et al, 1998; Seder et al, 1998) while simultaneously
inhibiting IL-4 production. Therefore, the deletion of either
cytokine would have the net effect of inhibiting ®brosis. Second, it
is possible that a common molecule in IL-4 and TGF-b signaling
pathways may be involved in the regulation of collagen gene
expression. This scenario suggests that the IL-4 and TGF-b
signaling intermediates act in a synergistic fashion to upregulate
extracellular matrix production. Support for this hypothesis was
provided by Nakashimia et al (1999) who found that stimulation
with leukemia inhibitory factor and bone morphogenic protein-1
results in the formation of a Smad1/STAT3 signaling complex and
this interaction is necessary for the development of astrocytes from
neural progenitor cell. In this way the combination of the two
cytokines may be necessary to generate the strength of signal
necessary to overcome a biologic threshold and induce the
®brogenic phenotype in TSK/+ mice. Therefore, the lack of
either cytokine would result in diminishing signal strength to a
point where it could no longer overcome this threshold and
effectively abrogate the ®brosis observed in TSK/+ mice.
In summary, our results demonstrate the in vivo effect of IL-4 and
TGF-b signaling on skin sclerosis in mice as illustrated in the lack of
cutaneous hyperplasia in TSK/+ IL-4Ra ±/± and, to a lesser
extent, in TSK/+ TGF-b +/± mice. These results may be exploited
for the development of new therapeutic approaches for scleroderma
and suggest a major part for these cytokines in ®brosis and wound
healing.
This work was supported by a grant from the Scleroderma Foundation and NIAID-
NIH grant PO1AI24671-12.
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